re-consideration of treatments for tumors diagnosed as so-called PNET. In this study, we propose the optimization of treatments for tumors diagnosed by the new classification to clarify which treatments were effective for the tumors those were diagnosed as PNET. MATERIALS AND METHODS: The tumor samples diagnosed as so-called PNETs were analyzed. The molecular information was extracted from tumor specimens. We used high throughput analysis with microarray, FISH, and immunohistochemistry. They all had treated in our institution in last 6 years and their clinical courses were followed by medical records. Informed parental consent was obtained from their guardians and this study was approved by the institutional review board of Juntendo university. RESULTS: Nine tumor samples were able to be analyzed and they are re-classified into high-grade glioma, sarcoma, embryonal tumors with multilayered rosettes, C19MC altered (ETMR). They resembled each other closely in morphology, and therefore, it was not able to be classified by histopathological findings. There was a case of pineoblastoma, whose molecular background suggested that the tumor was re-classified into neuroblastoma. In terms of diagnosis, we have succeeded in neuroblastoma cases so far, ETMRs were required multiple surgeries and radiations to maintain remissions. CONCLUSIONS: Re-classification of diagnosis based on the molecular background is necessary to clarify the optimization of treatments for pediatric brain tumors, and the comprehensive methods is required. We present our methods for molecular diagnosis in clinical field and future plans.

MPC-11

IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETARY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM

Hiroki Takesaki1, Kenichiro Ogawa1, Mitsuhiro Kakuta1, Yoko Yoko1, Mitsuhiro Takezaki1, Fumoto Aikawa2, Makoto Takashima1, Kosuke Ichimura1, Akinobu Ichimura1, Naoki Hamada1, Yoshitaka Narita1; 1Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital

BACKGROUND: Mutations in isocitrate dehydrogenase 1 or 2 genes (IDH1/2) frequently occur in lower-grade gliomas. Mutant IDH1/2 proteins gain a new ability to produce 2-hydroxyglutarate (2HG). IDH1/2 mutations have been related to be related with seizure through the structural similarity of 2HG to glutamate. We, therefore, sought to investigate the relationship between seizure and IDH1/2 mutations and to visualize tissue 2HG distribution in patients with diffuse gliomas. METHODS: We assessed 149 patients with diffuse glioma, and measured tissue 2HG concentrations in 104 patients by using liquid chromatography-tandem mass spectrometry. The matrix-assisted laser desorption/ionization high resolution mass spectrometry imaging (MALDI-HR-MSI) was used to visualize tissue 2HG distribution for 12 tissue samples. RESULTS: Seizure onset was observed in 34 among 56 (60.7%) patients with IDH1/2 mutant tumor, whereas in 18 among 93 (19.4%) patients with IDH1/2 wild-type tumor (<p=0.0001). The tissue 2HG concentration was significantly higher in IDH1/2 mutant tumor than in IDH1/2 wild-type tumor (median: 4862 ng/mg vs 75 ng/mg, <p=0.0001). Multivariate analysis, including tissue 2HG concentration, IDH1/2 status, histology, grade, and location, showed that IDH1/2 mutations was significantly correlated with seizure onset. The MALDI-HR-MSI showed that 2HG spread in various concentration independent of cellularity and also in extracellular space in IDH1/2 mutant tumor tissue. CONCLUSIONS: We demonstrated the association between IDH1/2 mutations and seizure, and the heterogeneous 2HG distribution not only in cellular area but also in extracellular space. These findings suggest the potential role of 2HG as an intercellular mediator to tumor environment, resulting in epileptogenesis formation.

MPC-12

ACCURACY OF INTRAOPERATIVE SIMPLE FLOW CYTOMETER FOR HIGH GRADE GLIOMA OPERATION COMPARED WITH INTRAOPERATIVE FROZEN DIAGNOSIS.

Kenichiro Asano1, Toshio Fumoto2, Akio Kamatari1,2, Keisuke Sugawara1,2, Koichi Kato2, Hiroki Ohkuma1, Akira Kuruse1,1 Department of Neurosurgery, Hiroshima University Graduate School of Medicine Zaifu-cho, 2Hiroshi-shi, Aomori, Japan

INTRODUCTION: Intraoperative simple flow cytometer (iFC) was developed in recently, we examined the correlation intraoperative frozen diagnosis (IOFD) and intraoperative frozen section of resection margin (IOMF) to iFC. MATERIAL AND METHOD: Total 33 cases of high grade glioma performed intraoperative operation in April 2017 ~ May 2019, and IOFD and IOMF were compared to iFC. Sample of iFC were retrieved just same developed in recently, we examined the correlation intraoperative frozen diagnosis (IOMF) and iFC of high grade glioma with MIB-1, and the correlation rate of grading was 17.2%. Correlation coefficients between MIB-1 and iFC of IOMF was r=0.5019 P=0.0065. Accuracy rate of IOFM was 46.8%, and concordance rate of grading was 35.5%. Correlation coefficients between MB-1 and iFC of IOFM was r=0.5899 P=0.0001. CONCLUSIONS: Although iFC accuracy rate of IFC of IOMF and IOFM were high, iFC concordance rates and grade were low. Correlation between MB-1 and iFC of IOFM was better than that of IOFD. Probably, iFC of IOFM was a little difficult because of sample heterozygosity.

MPC-14

BRAF V600E MUTANT OLIGODENDROGLIOMA-LIKE TUMORS WITH CHROMOSOMAL INSTABILITY IN ADOLESCENTS AND YOUNG ADULTS.

Kohei Fujioka1, Uri Tabori, Cynthia Hawkins; 1Department of Hematology/Oncology, Sattama Children’s Medical Center, Sattama, Japan

We performed genome-wide methylation analysis on 136 pediatric low grade glioma (PGBG) cases, including a pediatric case of glioblastoma multiforme classified as oligodendroglioma-1 like BRAF V600E mutant tumors with Recurrent gain of Chromosome 7 and loss of Chromosome 10 (OLIVER). Hierarchical clustering and t-stochastic neighbor embedding analyses cluster them with previously described pediatric-type low grade gliomas, separate from adult gliomas. OLIVERs exhibit distinct cellular behavior as temporal lobe lesions in adolescents and young adults, prolonged history of seizures and all are alive with no recurrence (follow-up 3.2 to 13.2 years). Morphologically, all showed oligodenroglioma-like features, including necrosis, perivascular pseudorosettes, perivascular halos, a chicken-wire pattern of branching capillaries and microcalcification. None showed astrocytic features or characteristics suggestive of high-grade tumors including necrosis or mitotic figures. All tumors harbored multiple chromosomal copy number abnormalities (more than 10 chromosomes per OLIVER), but none showed 1p/19q co-deletion or IDH1 mutation. Interestingly, one tumor showed a TERT promoter mutation. Although the series is small, OLIVER may represent a new category of IDH wild-type low grade glioma, which may be confused with molecular GBM. Further, they highlight the heterogeneity of IDH wild-type gliomas and the relatively indolent behavior of pediatric-type gliomas.

MPC-15

FEASIBILITY OF GLIOMA SPECIFIC ONCOPANEL IN THE DIAGNOSIS OF GLIOMA.

Koji Yoshimoto1, Nayuta Higa2, Toshiaki Akahane, Haimura Yonezawa1, Hirokazu Ujiie1, Akhide Tanimoto; 1Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

AIM: Molecular classification of glioma is a mandatory in the diagnosis of glioma according to the WHO 2016 classification of tumors of the central nervous system. However, WHO does not indicate the molecular methodology to be integrated, and the versatility and cost-effectiveness of molecular diagnosis is a concern. In this study, we evaluate the feasibility of a glioma specific tailored NGS panel where driver gene mutation and 1p/19q co-deletion can be analyzed in a single platform. MATERIALS AND METHODS: We developed a glioma specific tailored NGS panel consisting of 49 genes including IDH1/2, TP53, PTEN, EGFR, FGFR1, RB1, CDKNA2, and the TERT promoter. DNA was extracted from FFPE tumor tissues histologically identified by a pathologist, and from patient derived blood to serve as a control. In this system, gene mutations and copy number alterations can be precisely characterized, thus 1p/19q co-deletion can also be evaluated. We have analyzed 106 glioma patients (Grade II: 19 cases, Grade III: 23 cases, Grade IV: 64 cases) using this system.

RESULTS: From these 106 cases, IDH1 and TERT promoter mutations were detected in 33 cases (28%) and 55 cases (52%), respectively. 1p/19q co-deletion was detected in 19 cases (18%), with IDH1 mutations in all cases. In 57 Grade IV cases, TP53, PTEN, RB1, NF1, PDGFR mutations were detected in 25 cases (43%), 24 cases (41%), 10 cases (17%), 8 cases (14%) and 6 cases (10%). Although EGFR mutation frequency was low (3%), amplification was detected in 14 cases (24%). As for deletion, PTEN and CDKNA2 loci were deleted in 36 cases (62%) and 30 cases (52%) respectively. To note, MET alterations were detected in 2 cases. The cases in which histopathological diagnosis is difficult to make have a tendency to show atypical genetic alterations.

CONCLUSION: Diagnosis of glioma patients with this glioma-specific tailored NGS panel is feasible.

MPC-16

RAPID PROGRESSIVE SPINAL DIFFUSE MIDLINE GLIOMA, A CASE REPORT.

Tatsuya Takezaki1, Naoki Shinomura1, Junichiro Kuroda1, Takahiro Yamamoto1, Keishi Makino1

1Department of Neurosurgery, Saitama Children’s Medical Center, Saitama, Japan

We report a 16-year-old boy with rapid progressive spinal diffuse midline glioma (DMMG) with no known predisposing genetic factors. MRI revealed an expansile intramedullary enhancing lesion, which progressed at an alarming pace despite intensive therapy. This case highlights the importance of early diagnosis and management of DMMG.
A 17-year-old boy presented with a 2-week history of lower back pain, progressive gait difficulty and sensory deficit of bilateral lower limbs. Magnetic resonance imaging of the brain showed intramedullary tumor with spinal cord expansion from Th12 to L2 and irregular areas of enhancement. Histopathology and biopsy was performed. Hemorrhage and necrosis were shown small atypical cells, but most cells had too much degeneration and necrosis to confirm the diagnosis definitively. Leptomeningeal dissemination caused conscious disturbance, nuchal rigidity and epilepsy, 2 weeks after decomposition, we performed cordotomy again for a detailed diagnosis, to be found diffuse midline glioma, H3K27M mutant by immunohistochemical examination and DQG ANE. He was treated with combination of whole brain and spine radiation therapy and chemotherapy with temozolomide and bevacizumab. He is still alive over 6 months. The survival significance of H3K27M mutant in spinal gliomas is unclear. Further examinations are needed.

MPC-17
USEFULNESS OF INTRAOPERATIVE MOLECULAR DIAGNOSIS OF GLIOMA USING REAL-TIME PCR
Shunichi Koriyama1, Masayuki Nitta1, Kenta Masui, Takashi Murayama1, Taichi Saito1, Takashi Komori, Yoshihiro Muragaki, Takakazu Kawamata1; Department of Neurosurgery, Tokyo Women’s Medical University, Tokyo, Japan

BACKGROUNDs: Based on the comprehensive gene association studies, we recently, the revision was issued in 2016 WHO classification, integrating genetic information in glioma diagnosis. Many studies have been reported the correlation between each molecular subtype and prognosis in the new classification. Gliomas surgery is required to maximize tumor resection with functional preservation. Currently, our institute decides a surgical strategy based on the morphological diagnosis and genetic information from the obtained tissue during the operation. We evaluated the IDH 1/2 gene mutations and 1p/19q co-deletion by using real-time PCR intraoperatively. We report the usefulness of this method in this presentation. OBJECTIVE: 58 specimens obtained during surgery from March to November 2017, IDH 1/2 gene mutations and 1p/19q co-deletion were evaluated intraoperatively by real-time PCR. IDH 1/2 gene mutations were detected using HRM, and SNP genotyping was used for TERT promoter mutations expected as a surrogate marker for 1p/19q co-deletion. RESULT: Each gene mutation was detected in approximately 90 minutes from DNA extraction of obtained surgical tissue to analysis. The accuracy of HRM of IDH 1/2 mutations was 97.3% (72/74 cases) evaluated by the result of IDH1-R132H IHC or Sanger sequencing, and SNP genotyping of TERT promoter mutations was 94.3% (50/53 cases). There was no almost difference from final genetic information. CONCLUSION: Real-time PCR is feasible as an intraoperative molecular diagnosis. The accuracy of diagnosis is very high, and it can be evaluated in a short time, so it’s useful for decision making during operation.

MPC-18
CATEGORYIZATION OF LOWER GRADE GLIOMA USING ONCOPanel
Hiroiuki Uchida1, Toshikazu Akahane, Nayuta Higa2, Mari Kishimoto, Tsubasa Hiroki, Hajime Yonezawa1, Akhide Tanimoto, Koji Yoshimoto1; The Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

PURPOSE: We are developing a 48-gene Oncopanel (Kagoshima Brain Tumor 48 Oncopanel) specializing in glioma diagnosis. Clinical application of genetic diagnosis derived from genetic alterations detected by Oncopanel, including IDH mutation, 1p/19q-co-deletion, and other gene mutations in lower-grade glioma was verified. METHODS: The 48 genes consist of 24 genes related to glioma and 24 genes on chromosomes 1 and 19. DNA was extracted from tumor FFPE samples and blood samples, and then single nucleotide variants and copy number variants were detected using next-generation sequencer. RESULTS: Among the 99 diffuse glioma cases that had undergone Oncopanel analysis by July 2019, 40 cases diagnosed histologically as WHO grade 2 or 3 diffuse glioma were included. The integrated diagnosis by conventional gene analysis were Diffuse astrocytoma 10 cases, anaplastic astrocytoma 11 cases, oligodendroglioma 10 cases, anaplastic oligodendroglioma 9 cases. IDH1 mutation was detected in 117 cases, of which in 19 cases 1p/19q-co-deletion was detected, all with TERT mutation. Among 11 cases with 1p/19q non-co-deletion, ATRX mutation was detected in 10 cases and was almost mutually exclusive with TERT mutation. In 10 cases without IDH mutation, EGFR amplification or mutation was detected in 6 cases, of which 4 cases were accompanied by TERT mutation. DISCUSSION: KBT48 can detect TERT and ATRX mutations in a mutually exclusive manner and can improve the classification accuracy of oligodendroglioma and astrocytoma. Group with gene profiles similar to glioblastoma with EGFR amplification/mutation and TERT mutation can also be classified. CONCLUSIONS: In the diagnostic classification of lower-grade glioma, KBT48 can well classify into oligodendroglioma group, astrocytoma group and glioblastoma-like group, and is considered to be applicable in clinical practice.

NEUROIMAGING (NI)

NI-01
CONTRAST-ENHANCED MRI AND POSTERIOR EMISSION TOMOGRAPHY FOR DISTINGUISHING THE GRADE OF GLIOMA
Hiroaki Takes1, Enosuke Ohwash1, Yuka Ikegame1, Yoshitaka Asano1, Jun Shind1, Kazuhiro Miwa, Takeshi Ito, Kazutoshi Yokoyama, Noriuki Nakayama, Hirohito Yano, Shoiko Ikuta, Takashi Maruyama, Yoshihiro Muragaki, Tsu Iswama1; Department of Neurosurgery, Chubu medical center for prolonged traumatic brain dysfunction, Kizawa memorial hospital.

OBJECTIVE: Grading of glioma according to the WHO classification plays a major role in the treatment of patients with glioma. It is widely recognized that malignant gliomas exhibit contrast enhancement on MRI, whereas low-grade gliomas do not exhibit contrast enhancement. However, we sometimes encounter malignant gliomas without contrast enhancement on MRI. In this study, we evaluated the diagnostic accuracy of contrast-enhanced MRI and PET for distinguishing the WHO grade of glioma. METHODS: A total of 105 patients with newly diagnosed cerebral glioma were included in the study. All patients underwent 11C-Methionine (MET), 11C-Choline (CHO), 18F-Fluorodeoxyglucose (FDG) PET and MRI. The specificity and sensitivity of MRI contrast enhancement and mean T/N ratios of these three tracers for each WHO grade were analyzed. RESULTS: Contrast enhancement was observed in 35 patients (33%) of the total. Contrast enhancement was observed in 130% (3%) in grade 2, 84% (19%) in grade 3, and 26% (87%) in grade 4. The specificity and sensitivity of MRI for differentiating grade 2 from grade 3 was 11.1% and 54%, respectively. In contrast, the cutoff value, sensitivity, and specificity of each tracer for differentiating grade 2 from grade 3 were: 1.70, 66.7%, and 58.1% for MET; 2.15, 76.7%, and 51.2% for CHO; and 0.64, 80.0%, and 32.6% for FDG, respectively. DISCUSSION: A correlation between contrast enhancement of MRI and WHO grade was observed to some extent; however, only 19 grade 3 gliomas showed contrast enhancement. The sensitivity and specificity of PET for differentiating between grade 2 and 3 was relatively higher than that of MRI; however, it was not suitable for clinical use. CONCLUSION: Contrast-enhanced MRI may not be reliable for determining the WHO grade for glioma, in particular differentiating between grade 2 and 3. Comprehensive evaluation with MRI and PET may provide more accurate diagnosis.

NI-02
THE ASSOCIATION BETWEEN 11C-METHIONINE UPTAKE, IDH GENE MUTATION, AND MGMT PROMOTER METHYLATION IN PATIENTS WITH GRADE II AND III GLIOMAS
Yoshiko Okita1, Tomoko Shohuda, Daisuke Kanematsu, Ema Yoshioka, Yoshinori Kodama, Masayuki Mano, Manabu Kinoshita1, Masahiro Nonaka, Toshiyuki Fujinaka, Yonehiro Kanemura; Department of Neurosurgery, Osaka International Cancer Institute, Osaka, Japan

AIM: We evaluated the association between 11C-methionine positron emission tomography (11C-methionine PET) findings, isocitrate dehydrogenase (IDH) gene mutation, and MGMT promoter methylation in patients with grade II and III gliomas. MATERIALS AND METHODS: Data were collected from 40 patients with grade II and III gliomas who underwent both magnetic resonance imaging (MRI) and 11C-methionine positron emission tomography (PET) as part of their pre-surgical examination. We examined IDH mutation through DNA sequencing, and MGMT promoter methylation through quantitative methylation-specific polymerase chain reaction (PCR).

RESULTS: A threshold of MGMT promoter methylation of 1.0% was associated with tumor/normal tissue (T/N) ratio. The T/N ratio in samples with MGMT promoter methylation ≥1.0% was higher than that in samples with MGMT promoter methylation <1.0%, and the difference was statistically significant (p = 0.011). Reliable prediction of MGMT promoter methylation (≥1.0% vs ≤1.0%) was possible using the T/N ratio under the receiver operator characteristic (ROC) curve with a sensitivity and